Arch Therapeutics, Inc.
Healthcare · Surgical & Medical Instruments & Apparatus · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $75,724 | $15,652 | $11,565 | $0 | $0 | $0 |
| Operating income | −$5.0M | −$5.7M | −$6.4M | −$5.4M | −$1.5M | −$2.0M |
| Net income | −$7.0M | −$5.3M | −$6.2M | −$4.7M | $169,962 | −$1.6M |
| Total assets | $2.0M | $2.6M | $3.7M | $2.2M | $2.9M | $4.8M |
| Total liabilities | $9.5M | $6.8M | $4.7M | $3.7M | $3.7M | $3.5M |
| Equity | −$7.5M | −$4.2M | −$1.0M | −$1.5M | −$807,297 | $1.4M |
| EPS (diluted) | $-2.27 | $-0.02 | $-0.03 | $-0.02 | — | — |
| Shares out. | 4.7M | 249.9M | 237.2M | 193.0M | 187.9M | 164.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −6661.7%
- Net margin
- −9221.4%
- Return on equity
- 93.0%
- Return on assets
- −356.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 483.4%
- Debt / equity
- —
- Book value / share
- $-1.60
- Revenue growth (YoY)
- 383.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -146.63distress
- Accruals / assets
- −184.3%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Dec 31, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
- NT 10-Qmissed a reporting deadline ↗Feb 15, 2024
- NT 10-Kmissed a reporting deadline ↗Dec 29, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2023
- NT 10-Qmissed a reporting deadline ↗May 15, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Debt acceleration / triggering event · Delisting / listing-standard notice · Changed auditor · Other material eventMay 23, 2025
- Director / officer changeFeb 7, 2025
- Entered a material agreement · New financial obligation · Unregistered equity saleJan 23, 2025
- Entered a material agreement · New financial obligation · Unregistered equity saleNov 7, 2024
- Entered a material agreementNov 4, 2024
- Entered a material agreement · New financial obligation · Unregistered equity saleSep 26, 2024
- Entered a material agreementSep 19, 2024
- Entered a material agreement · New financial obligation · Unregistered equity saleSep 13, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.